EDSA - CIK 0001540159
Edesa Biotech, Inc. trades as EDSA. This page tracks Edesa Biotech, Inc. through 713 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin compressed from -374.7% to -1935.3% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-14 |
| Major company event | 8-K | 2026-05-14 |
The largest companies sharing Edesa Biotech, Inc.'s SEC industry classification (pharmaceutical preparations).
In its latest fiscal year Edesa Biotech, Inc. reported a net loss of $7.19M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.